Tumor-Associated Macrophages in Glioblastoma Multiforme—A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy? by Lapa, Constantin et al.
RESEARCH ARTICLE
Tumor-Associated Macrophages in
Glioblastoma Multiforme—A Suitable Target
for Somatostatin Receptor-Based Imaging
and Therapy?
Constantin Lapa1*, Thomas Linsenmann2, Katharina Lückerath1, Samuel Samnick1,
Ken Herrmann1, Carolin Stoffer3, Ralf-Ingo Ernestus2, Andreas K. Buck1, Mario Löhr2,
Camelia-Maria Monoranu3
1 Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany, 2 Department of
Neurosurgery, University Hospital Würzburg, Würzburg, Germany, 3 Department of Neuropathology,




Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Tumor-
associated macrophages (TAM) have been shown to promote malignant growth and to
correlate with poor prognosis. [1,4,7,10-tetraazacyclododecane-NN0,N@,N0@-tetraacetic
acid]-d-Phe1,Tyr3-octreotate (DOTATATE) labeled with Gallium-68 selectively binds to so-
matostatin receptor 2A (SSTR2A) which is specifically expressed and up-regulated in acti-
vated macrophages. On the other hand, the role of SSTR2A expression on the cell surface
of glioma cells has not been fully elucidated yet. The aim of this study was to non-invasively
assess SSTR2A expression of both glioma cells as well as macrophages in GBM.
Methods
15 samples of patient-derived GBM were stained immunohistochemically for macrophage
infiltration (CD68), proliferative activity (Ki67) as well as expression of SSTR2A. Anti-CD45
staining was performed to distinguish between resident microglia and tumor-infiltrating mac-
rophages. In a subcohort, positron emission tomography (PET) imaging using 68Ga-DOTA-
TATE was performed and the semiquantitatively evaluated tracer uptake was compared to
the results of immunohistochemistry.
Results
The amount of microglia/macrophages ranged from<10% to>50% in the tumor samples
with the vast majority being resident microglial cells. A strong SSTR2A immunostaining was
observed in endothelial cells of proliferating vessels, in neurons and neuropile. Only faint
immunostaining was identified on isolated microglial and tumor cells. Somatostatin receptor
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imaging revealed areas of increased tracer accumulation in every patient. However, reten-
tion of the tracer did not correlate with immunohistochemical staining patterns.
Conclusion
SSTR2A seems not to be overexpressed in GBM samples tested, neither on the cell surface
of resident microglia or infiltrating macrophages, nor on the surface of tumor cells. These
data suggest that somatostatin receptor directed imaging and treatment strategies are less
promising in GBM.
Introduction
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and rep-
resents approximately 65% of all newly diagnosed malignant gliomas [1]. GBM patients have
an extremely poor outcome with only 10% surviving 5 years after the initial diagnosis, and a
median survival of about 15 months, even after aggressive therapies including surgery, external
beam radiotherapy and chemotherapy [2–4]. The limited response to standard therapies is be-
lieved to result from tumor heterogeneity as well as diffuse infiltration into the normal brain
parenchyma [5].
GBM generally contains multiple morphologically diverse cell types that express neural,
glial and myeloid markers [6]. In fact, mesenchymal cells with characteristics of tumor-associ-
ated macrophages (TAM) and/or microglia can comprise up to 40% of GBM [7, 8]. TAM have
been shown to promote malignant glioma growth by creating a local immunosuppressive mi-
croenvironment, secreting pro-angiogenic factors and enhancing invasion mediated by the
production of soluble factors such as transforming growth factor-β (TGF-β), interleukin (IL)-
10, vascular endothelial growth factor, and matrix metallopeptidase-9 [9–14]. The extent of
TAM infiltration has been associated with poor prognosis in patients with breast, prostate,
bladder or cervical cancers [15–18]. In glioblastoma, the number of macrophages is higher
compared to that observed in low-grade gliomas, and correlates with the vascular density with-
in the tumor [19].
Somatostatin receptors (SSTR) are a family of G protein-coupled seven-transmembrane re-
ceptors of which at least five different subtypes (SSTR1-5) have been described. SSTR mediate
the effects of somatostatin, a regulatory peptide produced by neuroendocrine, inflammatory,
and immune cells [20]. The receptors differ in their molecular structure, tissue distribution, in-
tracellular signaling, and pharmacological characteristics [20, 21]. [1,4,7,10-tetraazacyclodode-
cane-NN0,N@,N0@-tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE) labeled with the
generator-derived positron-emitting isotope Gallium-68 (68Ga) selectively binds to somatostat-
in receptor 2A (SSTR2A) [22, 23]. 68Ga-DOTATATE positron emission tomography (PET) is
routinely used for the staging and restaging of neuroendocrine tumors [24]. Importantly,
SSTR2 was also found to be specifically expressed and up-regulated in human macrophages
[25–27]. Therefore, this tracer might be suitable for the assessment of macrophage infiltration
in GBM and thereby allowing risk stratification, indicating patients with a high amount of infil-
trating macrophages and, as a consequence, a worse prognosis.
On the other hand, several studies have reported conflicting results concerning the expres-
sion of SSTR2A on the cell surface of malignant gliomas. Some groups found a rather robust
receptor expression in human gliomas including GBM [28–30], others did not [31–32]. How-
ever, on the basis of SSTR-PET, successful treatment of GBM and meningioma using the
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somatostatin receptor-based radiopharmaceuticals 90Y-[1,4,7,10-tetraazacyclododecane-N,N0,
N@,N@0-tetraacetic acid0-d-Phe1,Tyr3]octreotide (90Y-DOTATOC) or 177Lu-[1,4,7,10-tetraaza-
cyclododecane-N,N0,N@,N@0-tetraacetic acid0-d-Phe1,Tyr3]octreotate (177Lu-DOTATATE) has
recently been described [33–35]. Therefore, there might be a therapeutic approach to GBM
using radiolabeled somatostatin analogs.
The aim of this study was to assess SSTR2A expression of both malignant glioma cells as
well as macrophages in GBM as a potential target for imaging and therapy. Additionally,
neuropathological findings were correlated to SSTR-PET imaging in three patients to evaluate
potential feasibility of PET in diagnosis and therapy planning.
Materials and Methods
Samples and histological characterization of tumors
We retrospectively evaluated specimens resected from 15 patients (10 males, 5 females) with
the initial diagnosis of glioblastoma multiforme (WHO grade IV) who underwent tumor resec-
tion at the Department of Neurosurgery of the University Hospital Würzburg between January
2012 and March 2013. Informed written consent was obtained from all patients.
All tumors were histologically assessed and graded on formaline fixed and paraffin embed-
ded tissue sections by an experienced neuropathologist (CMM), according to the criteria of
the World Health Organisation [36]. All specimens included the core of the tumors. In 14/15
cases (all samples except patient #1), the infiltration zone was examined for intra-tumoral het-
erogeneity of receptor expression. Paraffin sections (3 μm thick) were stained by applying
immunohistochemical methodology. Glial origin of the tumor cells was confirmed by the posi-
tive reaction with the glial fibrillary acid protein (GFAP,1:200, Clone 6F2, Dako, Hamburg,
Germany). Neurons and neuropile islands within tumor samples were identified by immuno-
histochemical staining with an antibody against synaptophysin (1:50, Clone SY38, Dako, Ham-
burg, Germany). To determine the proliferative activity of tumor cells, Ki-67 labeling index
was calculated after immunostaining for MIB-1 (monoclonal, clone Ki-67, 1:50, Dako, Ham-
burg, Germany) by determining the number of positive nuclei among 100 tumor cells per high
power field (HPF) (x400) in a total of 10 HPF per sample. An anti-CD68-antibody (1:200,
Clone IS609, Dako, Hamburg, Germany) was used to identify intratumoral microglial cells and
macrophages. Furthermore, to distinguish between local resident microglia and infiltrating
macrophages, staining for the Leucocyte Common Antigen (CD45, 1:100, Clone 2B11+PD7/
26, Dako, Hamburg, Germany) was performed. Sections were incubated overnight at 4°C with
the primary antibody. Antibody-binding was visualized using a labeled streptavidin-biotin
complex (LSAB, DCS, Hamburg, Germany) and the Envision System-horseradish peroxidase
(HRP) (DAB, Dako, Hamburg, Germany). All immunostained sections were counterstained
for 2 minutes with hematoxylin in order to identify tumoral or underlying parenchyma cells. A
visual semiquantitative relative assessment of macrophages and malignant glioma cells was
done. For this purpose, the fraction of labeled cells was graded using a scale from 0–20%, 20–
50% and>50% in correspondence to the visual grading “few”, “moderate” and “numerous”, re-
spectively, relative to the cell amount of the entire tumor sample.
SSTR2A immunohistochemistry
Adjacent paraffin sections (3 μm thick) were used for immunohistochemistry with a polyclonal
antibody against SSTR2A (1:100, Zytomed, Berlin, Germany) and with a monoclonal antibody
against SSTR2A (1:200, Clone LS-C75923, LifeSpan BioScience, Eching, Germany). Samples
from normal pancreas tissue were used as positive control, as recommended by the manufac-
turer. Dewaxed samples were pretreated with the antigen retrieval agent Target Retrieval
SSTR-PET/CT and Therapy in GBM
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Solution (TRS) pH 9.0 (Dako, Hamburg, Germany; Tris/EDTA) for 10 minutes in a high pres-
sure cooker. Thereafter, they were washed in TBS pH 7.6 followed by peroxidase blocking with
2.5% H2O2 for 15 min. Serum blocking was performed for 20 min. using 10% normal goat
serum (Invitrogen 50062Z, Darmstadt, Germany). For detection, link- and label-antibody
from the SS Multilink HRP kit (DCS, LP000-UL, Hamburg, Germany) and the Romuline-
AEC-Chromogen-kit (Zytomed, RAEC810L, Berlin, Germany) or the ultraView Universal
DAB Detection Kit (Ventana Medical Systems, 760–500, Darmstadt, Germany) were used ac-
cording to the manufacturer's instructions. All immunostained sections were counterstained
for 2 minutes with hematoxylin. Sections without exposure to the primary antibodies served as
negative controls as well as cross-sections exposed to human normal serum. Cross-sections de-
rived from human normal pancreas selectively staining pancreatic islet cells were used as
positive controls.
Imaging
In 3 patients (#2, 3 and 15), the possible relationship of 68Ga-DOTATATE-uptake and the den-
sity of macrophages/microglia within the malignant glioma was investigated. For this purpose,
routine magnet resonance (MR) imaging and SSTR-PET/CT with 68Ga-DOTATATE serving
as tracer was performed. One patient (#15) also underwent amino acid based PET with O-
(2-18F-fluoroethyl)-l-tyrosine (18F-FET). PET imaging was performed in the clinical routine as
part of the pre-operative diagnostic work-up and the imaging test was offered to patients on
the basis of compassionate use; written informed consent for the imaging procedures was ob-
tained. Consequently, additional approval was waived by the local ethics committee (Universi-
ty of Würzburg).
Non-invasive imaging of SSTR-2 expression and amino acid transport in
patients with glioma
Synthesis of the SSTR-2 specific ligand 68Ga-DOTATATE was carried out on a computer-as-
sisted synthesis module (Scintomics, Fürstenfeldbruck, Germany) using a modification of the
method previously described by Breeman et al. [37].
Imaging of SSTR expression was performed on a state-of-the-art PET/CT device (Siemens
Biograph mCT 64, Siemens, Knoxville, USA) consisting of a Lutetium oxyorthosilicate full-
ring PET scanner and a 64-slice spiral CT. 68Ga-DOTATATE (121 ± 12 MBq) was injected
intravenously. After 40–60 min, transmission data were acquired using spiral CT (80 mAs,
120 kV, a 512 × 512 matrix, 5 mm slice thickness, increment of 30 mm/s, rotation time of 0.5 s,
and pitch index of 0.8). Consecutively, PET emission data were acquired in three-dimensional
mode with a 200 × 200 matrix with 2 min emission time per bed position. After decay and
scatter correction, PET data were reconstructed iteratively with attenuation correction using a
dedicated software (HD-PET, Siemens Esoft, München, Germany).
18F-FET was synthesized in-house on a GE TRACERlab FX-FN synthesis module (GE Med-
ical Systems, Uppsala, Sweden) in analogy to the method previously described by Bourdier
et al. [38]. PET/CT was performed according to the guidelines for brain tumor imaging [39].
Static PET images were acquired 30 min after intravenous injection of 237 MBq 18F-FET. The
scan lasted for 10 min. Data acquisition as well as reconstruction parameters were the same as
for SSTR-PET/CT.
Magnetic resonance imaging
All 3 patients underwent routine MR imaging (3TMagnetom Trio MR; Siemens, München,
Germany) with a standard head coil (T1, T2, and FLAIR sequence). Axial T1-weighted images
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were obtained from the second cervical vertebral body to the vertex. Additionally, after intrave-
nous administration of contrast agent gadoteric acid (DOTAREM; Guerbet, Villepinte,
France), three-dimensional T1 weighted gradient echo sequences were performed for use in
intraoperative neuronavigation.
Image interpretation and data analysis
All imaging tests were reviewed independently and SSTR-PET findings were compared to MRI
and/or 18F-FET-PET results. All studies were analyzed by two experienced nuclear medicine
physicians (C.L., K.H.) who were aware of the clinical data.
68Ga-DOTATATE and 18F-FET uptake in the tissue were calculated as standardized uptake
value (SUV) by dividing the radioactivity (kBq/mL) in the tissue by the radioactivity injected
per gram of body weight.
Image analysis was performed as previously described [40]. In short, images were first in-
spected visually. Then the axial PET image displaying the maximum tumor uptake was select-
ed. Tumor regions of interest (ROIs) were defined in 2 ways. Firstly, a standardized 10 mm
circular region was placed over the area with the peak activity. This initial ROI was used to de-
rive the maximum standardized uptake value (SUVmax) and the mean standardized uptake
value. A reference region in the normal brain was defined by drawing a ROI (diameter of 25
mm) involving the entire contralateral hemisphere at the level of the centrum semiovale to de-
rive tumor-to-background ratios (TBRmean and TBRmax).
Correlation of imaging results with histopathology
In three patients (#2, 3 and 15), 68Ga-DOTATATE-PET/CT and MR images were transferred
to a neuronavigation system (Stealth Station S7, Medtronic Navigation, Louisville, USA) and
combined in image fusion planning (StealthMerge Image Registration, Medtronic Navigation,
Louisville, USA). During surgery of the gliomas, neuronavigated biopsy specimens were sepa-
rately obtained from areas with visually different 68Ga-DOTATATE-uptake by an experienced
neurosurgeon (M.L.) 3 samples out of areas with high, moderate and/or low 68Ga-DOTATATE
uptake were acquired from each patient and checked for macrophage infiltration. A total of
nine samples (3 per patient) were examined. After histological processing, the percentage of
microglia and macrophages was visually assessed, calculated and graded using the following
scale: 0–20%, 20–50% and>50% related to the total number of cells assessed for SSTR2A stain-
ing. For each patient, 3 different tumor areas with a diameter of 5 to 10 mm were examined
and correlated with the 68Ga-DOTATATE uptake level (SUVmax).
Results
Histopathological characterization of resected tumor samples
Specimens from 15 patients (10 males, 5 females) with the initial diagnosis of glioblastoma
multiforme were resected and subsequently analyzed. At time of diagnosis, the mean age of the
subjects was 62±12 y (range, 42–83 y). 6/15 tumors were located frontal and, 1/15 fronto-parie-
tal. 2/15 patients presented with parietal glioma, 1/15 with temporo-parietal GBM. In each 2/
15 patients the tumors were located temporal (n = 2) or occipital (n = 2), respectively; the re-
maining patient (1/15) suffered from temporo-occipital GBM. Symptoms varied according to
malignant glioma location within the brain and included motor weakness, visual symptoms,
language deficits, cognitive and personality changes as well as headaches and seizures. None of
the patients had undergone any previous treatment. Complete surgical resection could be
SSTR-PET/CT and Therapy in GBM
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performed in 5/15 patients, in the remainder (10/15) only sub-total or partial resection was
achieved according to pathological analysis and/or post-operative imaging.
11/15 patients died from GBM during follow-up (mean overall survival, 11±6 months), the
remaining 4 subjects are still alive.
13/15 tumor samples (87%) demonstrated a tumor cell burden>50%. In the remaining two
samples, malignant glioma cells comprised 20–50% of total cells. In all specimens, considerable
numbers of tumor associated macrophages could be detected: In 4/15 cases (27%), less than
20% of cells stained for CD68; in 10/15 samples (67%) infiltration was> 20% but< 50% and
in the remaining 1/15 samples (7%), more than 50% of the cells represented tumor associated
macrophages. To identify infiltrating monocytes/macrophages and lymphocytes (CD45high)
and to distinguish these from residential microglia cells (CD45low), tissue sections were ana-
lyzed for CD45 expression. In agreement with current literature, resident/ramified microglia
had a fainter CD45 immunostaining compared to recruited leukocytes which impressed as
round-globoid cells with strong immunoreactivity. However, in all 15 glioblastoma-specimens,
few CD45high cells were found, whereas numerous CD45low cells were present, indicating a low
number of tumor-infiltrating macrophages (S1 Fig.).
Cell proliferation, as assessed by MIB-1 (clone Ki-67), was lower than 50% in all samples.
Details are given in Table 1.
Expression of somatostatin receptor 2A (SSTR2A) in resected tumor
samples
Only faint SSTR2A immunostaining of single macrophages was detected independently of the
antibody used; therefore, no correlation to the relatively higher number of macrophages could
be demonstrated (Fig. 1). No clear differences between tumor-infiltrating macrophages and
resident microglial cells could be established. In addition, only single tumor cells showed a sim-
ilarly weak staining for SSTR2A. The staining was confined to the membrane and cytoplasma
whereas the nucleus was spared. Quantification was not feasible due to the very low number of
immunopositive cells (lower than 10%). In 14/15 cases (all except sample of patient #1), the tis-
sue sections included both the central core as well as invasive margins of the tumor (infiltration
Table 1. Distribution of macrophage infiltration, tumor cell burden and proliferation (visual assessment) in GBM samples.
Patient Age (years) Sex Macrophage infiltration (%) Tumor cell (%) Ki 67 (%)
1 72 F 20–50 >50 25–30
2 83 F Table 2 Table 2 20–30
3 69 M Table 2 Table 2 20–30
4 51 F 20–50 >50 15–25
5 72 M 20–50 >50 20
6 48 M <20 >50 30
7 56 M 20–50 >50 10–20
8 70 M 20–50 >50 25
9 77 F <20 >50 40–50
10 42 M >50 20–50 15
11 62 M <20 >50 15–30
12 60 M 20–50 >50 25
13 72 M 20–50 >50 15–20
14 51 M 20–50 >50 15–20
15 51 F Table 2 Table 2 10–15
doi:10.1371/journal.pone.0122269.t001
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Fig 1. Immunohistochemical staining of SSTR2A (sample of patient #15). (A) non-tumoral cortex with
strong reaction in neurons (arrows) and neuropile (magnification: 100x). Left inset: Negative control. Right
inset: positive control (normal pancreas) with strong reaction in an islet of Langerhans. (B) CD68 staining
depicting high microglia/macrophage infiltration area and (C) SSTR2A immunostaining of an adjacent area
showing strong reaction in endothelium (arrows) and in single glioma cells (arrowheads) (magnification:
100x).
doi:10.1371/journal.pone.0122269.g001
SSTR-PET/CT and Therapy in GBM
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zone). No difference regarding SSTR2A expression between both areas was observed with a
very low number of SSTR-positive cells in all areas. In fact, a strong positive reaction was seen
only in adjacent cortical areas (in neurons and neuropile) and in entrapped neurons in some
tumor areas (S2 Fig.).
In contrast, in all samples examined a strong SSTR2A staining of intratumoral vascular en-
dothelial cells, adjacent neuropile and neuronal cells could be observed. Non-tumoral astro-
cytes and oligodendrocytes, on the other hand, did not express SSTR2A. In some cases, a fine
granular staining was observed also in the protoplasmic background of the tumor tissue.
A representative example of immunostaining in one resected tumor sample is given in S3
Fig. (monoclonal and polyclonal anti-SSTR2-antibody).
SSTR-PET imaging of glioblastoma multiforme
All 3 patients who underwent SSTR-PET/CT showed areas of markedly increased 68Ga-
DOTATATE uptake (Fig. 2). Median SUVmean was 3.9 (range 3.5–4.5), median SUVmax 5.1
(range 4.5–5.8), median TBRmean 193 (range 175–225) and median TBRmax was 130 (range
116–175). Those excellent tumor-to-background contrasts are due to extremely low back-
ground activity, ranging from 0.02 to 0.05. Interestingly, 68Ga-DOTATATE uptake was highest
in areas with distinct contrast enhancement on MR imaging (Fig. 3). On visual inspection, the
pattern of 68Ga-DOTATATE uptake matched 18F-FET accumulation regarding size and shape
(Fig. 4). However, 68Ga-DOTATATE allowed better tumor delineation than 18F-FET: In the
one patient (# 15) undergoing both scans, TBRmean und TBRmax were 180 and 125 for
68Ga-
DOTATATE and 3.9 and 3.6 for 18F-FET, respectively.
Comparison of 68Ga-DOTATATE uptake and histopathological findings
The percentage of tumor cells ranged from<20–>50% with>50% in 6/9 of samples (3 sam-
ples per patient #2, 3, 15). In one surgery specimen (1/9; #3.3), numbers ranged from 20–50%,
in the remaining 2 cases (2/9; #3.1, 15.3), malignant glioma cells made up less than 20% of
the sample.
Macrophage numbers were also variable, ranging from<20% to>50%. In 4/9 specimens,
tumor-associated macrophages comprised less than 20% of cells. In 4/9 samples 20–50%, and
in the remaining specimen more than 50%, respectively. However, the number of SSTR-posi-
tive cells did not exceed 10% in any sample independent of tracer uptake. Therefore, no corre-
lation between macrophage or malignant glioma cell numbers and tracer accumulation was
observed (Table 2).
Discussion
Tumor-associated macrophages (TAM) are generally known to promote the invasion, growth,
and angiogenesis of various tumors. This is the first report to assess the expression of somato-
statin receptor 2A in TAMs in glioblastoma multiforme. In our cohort, immunohistochemistry
managed to depict CD68-positive infiltrates comprising up to 20–50% of the individual tumor
samples. This finding is in line with the literature reporting that TAMs can comprise up to 40%
of all cells in GBM [7, 8]. Therefore, we hypothesized some role for SSTR-PET/CT in the depic-
tion of macrophage infiltration and, thus, individual prognosis. Additionally, since local pep-
tide receptor-mediated radiotherapy in GBM has been described [31–33], feasibility of a
“theranostic” approach using SSTR-PET/CT for evaluation of receptor expression and conse-
cutive systemic peptide radio receptor therapy was to be assessed. However, robust SSTR2A
staining was observed only in single macrophages. This finding is not in line with previous re-
ports that found a high expression of SSTR2A on the surface of peripheral activated
SSTR-PET/CT and Therapy in GBM
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macrophages in vitro [26]. However, as the other groups did not investigate glioma tissues,
final conclusions cannot be drawn at this time.
Several authors have reported a robust somatostatin receptor expression on the surface of
malignant glioma cells [28–30]. However, in our series of GBM samples with considerable
tumor cell burden (>50% in all but two samples), we could not detect any relevant receptor ex-
pression on the GBM tumor cell surface. On the contrary, SSTR2A showed a higher expression
in the normal brain parenchyma including neurons and vessels. This finding was consistent in
both the tumor core as well as the infiltration zone.
Fig 2. Tracer distribution of 68Ga-DOTATATE in GBM. Three examples of increased 68Ga-DOTATATE uptake in Glioblastomamultiforme. Markedly,
partly inhomogeneous tracer accumulation can be depicted in each patient. Shown are axial views of CT, SSTR-PET as well as fused PET/CT images.
doi:10.1371/journal.pone.0122269.g002
SSTR-PET/CT and Therapy in GBM
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Interestingly, in the three patients who underwent SSTR-PET/CT prior to brain surgery,
68Ga-DOTATATE uptake within tumor tissue could be observed in all patients. However, in-
tensity of radiotracer accumulation did not correlate with macrophage density in histology. On
the contrary, a better correlation of 68Ga-DOTATATE uptake could be observed with contrast
enhancement in magnetic resonance imaging, thereby questioning tracer specificity. In the
light of these findings, reports on successful treatment of GBM with 90Y-DOTATATE on the
basis of a positive pre-therapeutic PET scan cannot be interpreted as examples of targeted ther-
apies [33]. Although some therapeutic effects can be achieved due to high radiation doses deliv-
ered directly in the surgical cavity, the notion that those effects are achieved by specific binding
of radiopharmaceutical to TAMs and/or malignant glioma cells is highly questionable. On the
contrary, somatostatin receptor-targeted tracer uptake in GBM seems to be highly unspecific
and caused by the disruption of the blood-brain barrier.
This study has several limitations. A rather small sample size was included. Since the tumors
were not examined in toto, histology is prone to sampling bias. Macrophage labelling with
CD68 specific antibodies does not necessarily allow to discriminate macrophages from tumor
Fig 3. Comparison of 68Ga-DOTATATE uptake andMR contrast agent enhancement. In all 3 patients, there is a marked overlap between 68Ga-
DOTATATE uptake and MR contrast agent enhancement. Radiotracer accumulation is most pronounced in areas with intense contrast enhancement.
Shown are axial views of contrast-enhanced T1-weighted MR as well as fused MR/PET images.
doi:10.1371/journal.pone.0122269.g003
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cells since both cell types may present with positive staining patterns [41,42]. However, SSTR
expression was not sufficient in all samples so that the assignment of receptor expression to the
tumor cell compartment or to cells of the immune system seems less relevant in our series. PET
imaging was available in only three patients. Since we did not perform further experiments re-
garding macrophage differentiation, the reason for the obvious loss of the surface receptor can
only be hypothesized. It is known that TAMmay differentiate into two profiles, M1 and M2
[43, 44]. The classical activation is caused by stimuli like interferon-γ or tumor-necrosis-fac-
tor-α and results in a pro-inflammatory activation state called M1. The alternative pathway is
induced by interleukin-4 or interleukin-13 and leads to a rather immunosuppressive state. This
M2 polarization has been found to correlate with glioma malignancy and to represent the pre-
dominant macrophage population in GBM. This condition is linked to increased tumor inva-
siveness, higher glioma proliferation rates and poorer prognosis [45, 46]. Potentially, M2
differentiation of macrophages within the tumor-microenvironment of GBM leads to a
Fig 4. Comparison of 68Ga-DOTATATE and 18F-FET in GBM. A single patient (#15) underwent both SSTR- as well as amino acid-based PET. Both
modalities show highly comparable tracer uptake.
doi:10.1371/journal.pone.0122269.g004
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decreased SSTR expression. An optimal therapeutic scenario would include a high receptor ex-
pression by M2 and a low expression by M1 macrophages. However, we could not observe any
relevant SSTR2A expression in all our samples (including tumor core as well as margins). As
we focused on the potential of the receptor as a target for radiopeptide therapy, the question of
macrophage differentiation is beyond the scope of the present study. To the best of our knowl-
edge, there has not been any systematic assessment of this question so far.
On the other hand, it might be possible that only tumor-infiltrating macrophages express
SSTR2A, whereas the resident microglia does not. In our series, we could identify few infiltrat-
ing cells so that a final conclusion concerning their receptor expression level cannot be drawn
yet. However, since numbers of glioma-infiltrating monocytes/macrophages were low, they do
not represent a good target for SSTR-based therapeutic interventions.
Although first results regarding local instillation of radiolabeled somatostatin analogs have
yielded encouraging results, our findings question a role for peptide receptor-based therapy as
a novel treatment approach in GBM. Furthermore, molecular imaging using SSTR-PET/CT
seems not to be perfectly suited to elucidate the amount of TAMs. Even the possible application
of 68Ga-DOTATATE to delineate tumor tissue (given its very similar distribution in compari-
son to 18F-FET) in settings in which a cyclotron is not available is rendered doubtful given the
unspecific tracer distribution.
In conclusion, somatostatin receptor-directed imaging or therapy may represent a less
favourable approach in glioblastoma multiforme. Larger trails are needed to further assess its
use in the diagnostic or therapeutic management of GBM.
Supporting Information
S1 Fig. Immunohistochemical staining of CD45 (sample of patient #5) to distinguish be-
tween tumor-infiltrating monocytes/macrophages (CD45high) and resident microglia
(CD45low). (A) Few CD45high cells are discernable, indicating a low number of tumor-infiltrat-
ing macrophages (magnification: 100x). (B) Weak staining (CD45low) in tumor associated
microglia. These cells are well recognizable by their spindle-shaped (black arrows) or more
ramified cytoplasm (red arrow) (magnification: 400x). (C) Strong staining (CD45high) in
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Tumor cells
(% of entire sample)
SSTR2 positive cells (%) 68Ga-DOTATATE uptake level
1 20–50 >50 <10 high
2 <20 >50 <10 low




(% of entire sample)
Tumor cells
(% of entire sample)
SSTR2 positive cells (%) 68Ga-DOTATATE uptake level
1 <20 <20 <10 moderate
2 20–50 >50 <10 high




(% of entire sample)
Tumor cells
(% of entire sample)
SSTR2 positive cells (%) 68Ga-DOTATATE uptake level
1 >50 >50 <10 high
2 20–50 >50 <10 high
3 <20 <20 <10 moderate
doi:10.1371/journal.pone.0122269.t002
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infiltrating macrophages. These cells possess a rounded-globoid cytoplasm (magnification:
400x).
(TIF)
S2 Fig. Immunohistochemical staining of SSTR2A (sample of patient #8) including (A) the
core of the tumor and (B) the infiltration zone (magnification: 100x). No significant expres-
sion of SSTR2A by tumor cells or macrophages could be detected. Instead, SSTR2A-positivity
could be detected in (A) normal vessel walls and (B) in neurons and neuropile (arrows). Panel
(C) gives an example of a strongly stained neuron (magnification: 200x).
(TIF)
S3 Fig. A representative example of immunostaining in one resected tumor sample with
(A) a monoclonal and (B) a polyclonal anti-SSTR2A-antibody (sample of patient #3).With
both antibodies, only few SSTR2A-positive cells can be detected (magnification: 100x).
(TIF)
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